Mark Schuiveling

Mark Schuiveling

Auto-generated profile, based on publicly available information

Mark Schuiveling

Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Heidelberglaan 100, 3584 CG Utrecht, the Netherlands

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 January 2025 in GigaScience
Verified
Journal Article
Open access
MSMark Schuiveling
Mark Schuiveling
HLHong Liu
Hong Liu
DEDaniel Eek
Daniel Eek
GBGerben Eise Breimer
Gerben Eise Breimer
Karijn SuijkerbuijkKarijn Suijkerbuijk
Karijn Suijkerbuijk
MVMitko Veta
Mitko Veta
Background: Melanoma is an aggressive form of skin cancer in which tumor-infiltrating lymphocytes (TILs) are a biomarker for recurrence and treatment response. Manual TIL assessment is prone to interobserver variability, and current deep learning models are not publicly accessible or have low performance. Deep learning models, however, have the potential of consistent spatial evaluation of TILs and other immune cell subsets with the potential of improved prognostic and predictive value. To make the development of these models possible, we created the Panoptic Segmentation of nUclei and tissue in advanced MelanomA (PUMA) dataset and assessed the performance of several state-of-the-art deep learning models. In addition, we show how to improve model performance further by using heuristic postprocessing in which nuclei classes are updated based on their tissue localization. Results: The PUMA dataset includes 155 primary and 155 metastatic melanoma hematoxylin and eosin–stained regions of interest with nuclei and tissue annotations from a single melanoma referral institution. The Hover-NeXt model, trained on the PUMA dataset, demonstrated the best performance for lymphocyte detection, approaching human interobserver agreement. In addition, heuristic postprocessing of deep learning models improved the detection of noncommon classes, such as epithelial nuclei. Conclusion: The PUMA dataset is the first melanoma-specific dataset that can be used to develop melanoma-specific nuclei and tissue segmentation models. These models can, in turn, be used for prognostic and predictive biomarker development. Incorporating tissue and nuclei segmentation is a step toward improved deep learning nuclei segmentation performance. To support the development of these models, this dataset is used in the PUMA challenge.

30 June 2024 in European Journal of Cancer
Verified
Journal Article
Open access
IDIsabella A.J. van Duin
Isabella A.J. van Duin
MSMark Schuiveling
Mark Schuiveling
LMLaurens S. ter Maat
Laurens S. ter Maat
WAWouter Anton Christiaan van Amsterdam
Wouter Anton Christiaan van Amsterdam
FBFranchette van Den Berkmortel
Franchette van Den Berkmortel
Karijn SuijkerbuijkKarijn Suijkerbuijk
Karijn Suijkerbuijk
The presence of tumor-infiltrating lymphocytes (TILs) in melanoma has been linked to survival. Their predictive capability for immune checkpoint inhibition (ICI) response remains uncertain. Therefore, we investigated the association between treatment response and TILs in the largest cohort to date and analyzed if this association was independent of known clinical predictors. In this multicenter cohort study, patients who received first-line anti-PD1 ± anti-CTLA4 for advanced melanoma were identified. TILs were scored on hematoxylin and eosin (H&E) slides of primary melanoma and pre-treatment metastases using the validated TILs-WG, Clark and MIA score. The primary outcome was objective response rate (ORR), with progression free survival and overall survival being secondary outcomes. Univariable and multivariable logistic regression and Cox proportional hazard were performed, adjusting for known clinical predictors. Metastatic melanoma specimens were available for 650 patients and primary specimens for 565 patients. No association was found in primary melanoma specimens. In metastatic specimens, a 10-point increase in the TILs-WG score was associated with a higher probability of response (aOR 1.17, 95 % CI 1.07-1.28), increased PFS (HR 0.93, 95 % CI 0.87-0.996), and OS (HR 0.94, 95 % CI 0.89-0.99). When categorized, patients in the highest tertile TILs-WG score (15-100 %) compared to the lowest tertile (0 %) had a longer median PFS (13.1 vs. 7.3 months, p = 0.04) and OS (49.4 vs. 19.5 months, p = 0.003). Similar results were noted using the MIA and Clark scores. In advanced melanoma patients, TIL patterns on H&E slides of pre-treatment metastases, regardless of measurement method, are independently associated with ICI response. TILs are easily scored on readily available H&Es, facilitating the use of this biomarker in clinical practice.

20 February 2025 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
MSMark Schuiveling
Mark Schuiveling
LMLaurens S Ter Maat
Laurens S Ter Maat
IDIsabella A J Van Duin
Isabella A J Van Duin
RVRik J Verheijden
Rik J Verheijden
MTMax F Troenokarso
Max F Troenokarso
KSKarijn P M Suijkerbuijk
Karijn P M Suijkerbuijk
Background: The association of body composition with checkpoint inhibitor outcomes in melanoma is a matter of ongoing debate. In this study, we aim to investigate body mass index (BMI) alongside computed tomography (CT)-derived body composition metrics in the largest cohort to date. Methods: Patients treated with first-line anti-PD1 ± anti-CTLA4 for advanced melanoma were retrospectively identified from 11 melanoma centers in The Netherlands. From baseline CT scans, 5 body composition metrics were extracted: subcutaneous adipose tissue index, visceral adipose tissue index, skeletal muscle index, density, and gauge. These metrics were correlated in univariable and multivariable Cox proportional hazards analysis with progression-free survival, overall survival, and melanoma-specific survival (PFS, OS, and MSS). Results: A total of 1471 eligible patients were included. Median PFS and OS were 9.1 and 38.1 months, respectively. Worse PFS was observed in underweight patients (multivariable hazard ratio [HR] = 1.86, 95% CI = 1.14 to 3.06). Furthermore, prolonged OS was observed in patients with higher skeletal muscle density (multivariable HR = 0.88, 95% CI = 0.81 to 0.97) and gauge (multivariable HR = 0.61, 95% CI = 0.82 to 0.998), whereas higher visceral adipose tissue index was associated with worse OS (multivariable HR = 1.12, 95% CI = 1.04 to 1.22). No association with survival outcomes was found for overweight, obesity, or subcutaneous adipose tissue. Conclusion: Our findings suggest that underweight BMI is associated with worse PFS, whereas higher skeletal muscle density and lower visceral adipose tissue index were associated with improved OS. These associations were independent of known prognostic factors, including sex, age, performance status, and extent of disease. No significant association between higher BMI and survival outcomes was observed.

13 June 2024 in Immuno-Oncology and Technology
Verified
Journal Article
Open access
IDI.A.J. van Duin
I.A.J. van Duin
MSM. Schuiveling
M. Schuiveling
LML.S. ter Maat
L.S. ter Maat
MVMitko Veta
Mitko Veta
MEM.J.M. van Eijs
M.J.M. van Eijs
Karijn SuijkerbuijkKarijn Suijkerbuijk
Karijn Suijkerbuijk
The predictive value of tumor-infiltrating lymphocytes (TILs) in immune-related adverse event (irAE) development remains unknown, although an association between tumor immunogenicity and irAEs has been suggested. We investigated the association between TIL abundance in pretreatment primary and metastasis specimens and the subsequent development of severe irAEs. We retrospectively identified patients with advanced cutaneous melanoma who received first-line anti-programmed cell death protein 1 (PD-1) with or without anti-cytotoxic T-lymphocyte associated protein 4 (anti-CTLA-4) from 10 hospitals in the Netherlands. TILs were scored on representative hematoxylin and eosin (H&E) stains of the primary melanoma and pretreatment melanoma metastasis as ‘absent’, ‘nonbrisk’, or ‘brisk’. A univariable logistic regression analysis was carried out to assess the association between the TIL scores and the development of severe irAEs. Fine and Gray subdistribution hazard models were used to estimate the cumulative incidence of severe irAEs. Of the 1346 eligible patients, 536 patients had primary melanoma specimens available, and 613 patients had metastasis specimens available. Severe irAEs occurred in 15% of anti-PD-1-treated patients and 49% of anti-PD-1 + anti-CTLA-4-treated patients. The presence of TILs was not associated with the occurrence of grade ≥3 irAEs in primary melanoma specimens (P = 0.70) nor pretreatment metastasis specimens (P = 0.91). In the univariable analysis, patients with brisk TILs did not have a higher chance of developing severe irAEs compared with patients with absent TILs, for both primary specimen (odds ratio 1.15, 95% confidence interval 0.60-2.18) and metastasis specimen (odds ratio 0.77, 95% confidence interval 0.37-1.59). There was also no significant difference in the lifetime risk or timing of the development of severe irAEs in patients with TILs present compared with patients with TILs absent. There was no association between the TIL scores on H&E-stained slides from the primary melanoma or pretreatment metastasis and the development of grade 3 or higher irAEs. Additionally, no correlation was found between the presence of TILs and the timing of irAEs.

25 May 2026 in European Journal of Cancer
Verified
Journal Article
Open access
MSMark Schuiveling
Mark Schuiveling
IDIsabella A.J. van Duin
Isabella A.J. van Duin
LMLaurens S. ter Maat
Laurens S. ter Maat
JWJanneke C. van der Weerd
Janneke C. van der Weerd
RVRik J Verheijden
Rik J Verheijden
KSKarijn P.M. Suijkerbuijk
Karijn P.M. Suijkerbuijk
Readily available predictive biomarkers for immune checkpoint inhibitor (ICI) response in advanced melanoma are limited. This study evaluates the predictive value of AI-based histopathology analysis. Patients with advanced cutaneous melanoma treated with first-line anti-PD1 ±anti-CTLA4 between 2016 and 2023 across 11 Dutch centers were retrospectively identified using prospectively collected registry data. Pre-treatment H&E-stained metastatic slides were collected from 30 pathology labs and analyzed using 14 foundation models combined with attention-based or clustering-constrained multiple-instance learning. Primary outcome was best overall response (ORR) (RECIST 1.1) assessed through leave-one-hospital-out cross-validation. Response probabilities were added to a clinical model built with AIC-based backward selection (including WHO performance status, liver metastases, LDH, ICI-type, AJCC stage, brain metastases). Feature embedding clusters were labelled by three pathologists blinded to outcomes to assess histology driving predictions. Of 1935 patients, 1177 had a pre-treatment metastatic specimen available, most commonly lymph node or skin/soft tissue; 35.3% was treated with anti-PD1 +anti-CTLA4 combination therapy. ORR was 56.7% (n = 667/1177). The best AI-based model achieved an AUROC of 0.63 (95% CI:0.60-0.66) with overestimated risk. Combining the AI-based analysis with clinical information increased AUROC to 0.66 (95% CI:0.63-0.69) with improved calibration. Model predictions were driven by immune infiltration and epithelioid morphology for response, and by spindle-cell morphology, and necrosis for non-response. AI-based analysis of diagnostic pre-treatment metastatic melanoma samples predicts ICI outcomes by using explainable histological features, such as immune infiltration, cell morphology, and necrosis. The predictive performance of the AI-based analysis improves further upon addition of clinical information.

18 November 2025 in Communications Medicine
Verified
Journal Article
Open access
PDF file
MEMick J. M. van Eijs
Mick J. M. van Eijs
MWM. Marlot van der Wal
M. Marlot van der Wal
HKHedi-Britt Klotškova
Hedi-Britt Klotškova
NDNoël M. M. Dautzenberg
Noël M. M. Dautzenberg
MSMark Schuiveling
Mark Schuiveling
Karijn SuijkerbuijkKarijn Suijkerbuijk
Karijn Suijkerbuijk
Background High-dose steroids constitute the cornerstone of first-line treatment for immune-related adverse events (irAEs) associated with immune checkpoint inhibitors, but compromise antitumor immunity. A deeper understanding of irAEs and their response to steroids can improve management. Methods Using a multi-omics approach, we investigated blood- and tissue-based correlates of steroid response, focusing on gastro-intestinal irAEs, in the largest cohort to date. Results Here we show clear trends for elevated TC1/TC17 CD8+ T cells and Th1/Th7-associated interleukins before steroid initiation, and persistent (CD8+) T cell activation after initiation of steroids in blood of steroid non-responders. Cross-sectional analysis of colitis tissue suggested lower lymphocyte infiltration within 24 h in steroid responders. Peripheral T cell PD-1 receptor occupancy was unrelated to steroid response. Non-responders’ colitis tissue was enriched with activated CD4+ memory T cells and a pronounced type 1/17 immune response. Conclusions These findings highlight rapid steroid effects on circulating cells and irAE-affected tissue and support that an enhanced type 1/type 17 response may be associated with steroid non-response in irAEs. Validation of these findings in larger cohorts is warranted.